24/7 Market News Snapshot 06 March, 2025 – Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

March 6, 2025

DENVER, Colo., 06 March, 2025 (247marketnews.com) – (NASDAQ:LXRX) are discussed in this article.
Lexicon Pharmaceuticals, Inc. has demonstrated impressive performance, with its stock opening at $0.333 and experiencing a notable surge of approximately 17.56% to trade at $0.395. This bullish activity reflects heightened investor interest evidenced by a robust trading volume of 12.27 million shares, marking a substantial improvement from the previous session’s close of $0.336. Such price movements may indicate a momentum shift, driven by either positive market sentiment or favorable news related to the company’s clinical advancements.

In recent updates, Lexicon reported successful topline results from the Phase 2b PROGRESS study for pilavapadin (LX9211), an innovative non-opioid oral therapy developed for Diabetic Peripheral Neuropathic Pain (DPNP). The results highlighted a significant reduction in pain at the 10 mg dosage, surpassing placebo outcomes and fulfilling crucial study objectives. These findings set the stage for anticipated Phase 3 trials scheduled for 2025.

Dr. Mike Exton, CEO of Lexicon, emphasized the meaningful implications of these results, stating, “Our ability to progress pilavapadin underscores our focused commitment to advancing our robust R&D pipeline, which is central to our Lead to Succeed strategy.” The company aims to address the urgent need for novel neuropathic pain therapies, the first new oral option in over two decades.

Lexicon also outlined its strategic growth initiatives, including plans to file an Investigational New Drug (IND) application for LX9851 in 2025, which targets obesity and related cardiometabolic disorders. Additionally, it is actively enrolling participants in the pivotal Phase 3 SONATA trial for sotagliflozin as a treatment for hypertrophic cardiomyopathy (HCM). Throughout this period, the company reported a revenue increase to $26.6 million in Q4 2024, driven primarily by elevated sales of INPEFA and a significant licensing agreement. As investments in R&D rise, Lexicon remains steadfast in its mission to pioneer transformative medicines that enhance patient quality of life. Further details will be provided in upcoming communications, reflecting the company’s commitment to innovation and operational excellence.

Related news for (LXRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.